We are live on ! Find out more
PJP icon

Invesco Pharmaceuticals ETF

119 hedge funds and large institutions have $151M invested in Invesco Pharmaceuticals ETF in 2026 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 33 increasing their positions, 21 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

155% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 11

118% more capital invested

Capital invested by funds: $69.2M → $151M (+$81.8M)

57% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 21

15.89% more ownership

Funds ownership: 21.99%37.88% (+16%)

13% more funds holding

Funds holding: 105119 (+14)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $259K

Holders
119
Holders Change
+14
Holders Change %
+13.33%
% of All Funds
1.46%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
28
Increased
33
Reduced
21
Closed
11
Calls
Puts
$259K
Net Calls
-$259K
Net Calls Change
-$259K
Name Holding Trade Value Shares
Change
Change in
Stake
JWCA
51
J.W. Cole Advisors
Florida
$302K +$211 +2 +0.1%
UCFA
52
United Capital Financial Advisors
Texas
$297K -$30.4K -288 -9%
Creative Planning
53
Creative Planning
Kansas
$289K +$24.3K +230 +9%
SFPG
54
Stonebridge Financial Planning Group
Florida
$282K -$20.2K -191 -7%
Mariner
55
Mariner
Kansas
$266K -$71.1K -673 -21%
AF
56
Allworth Financial
California
$264K +$211 +2 +0.1%
CAPTRUST Financial Advisors
57
CAPTRUST Financial Advisors
North Carolina
$263K
CB
58
Commerce Bank
Missouri
$254K
HEM
59
Henson-Edgewater Management
Ohio
$254K
CBU
60
CIBC Bancorp USA
Illinois
$228K +$232K +2,200 New
QCM
61
Quantinno Capital Management
New York
$228K +$232K +2,193 New
FPAS
62
Focus Partners Advisor Solutions
Missouri
$216K +$106 +1 +0%
Fidelity Investments
63
Fidelity Investments
Massachusetts
$210K -$163K -1,543 -43%
SPIA
64
Steward Partners Investment Advisory
New York
$207K +$10.6K +100 +5%
TRCT
65
Tower Research Capital (TRC)
New York
$189K +$193K +1,825 New
HI
66
Harbour Investments
Wisconsin
$184K +$148K +1,399 +378%
GWM
67
Geneos Wealth Management
Colorado
$179K +$35.4K +335 +24%
PNC Financial Services Group
68
PNC Financial Services Group
Pennsylvania
$137K
VNA
69
Valley National Advisers
Pennsylvania
$137K -$90.6K -858 -39%
Rockefeller Capital Management
70
Rockefeller Capital Management
New York
$128K +$317 +3 +0.2%
JP Morgan Chase
71
JP Morgan Chase
New York
$101K
IAIM
72
International Assets Investment Management
Florida
$63.6K
NSIM
73
North Star Investment Management
Illinois
$62.3K
AWM
74
AE Wealth Management
Kansas
$61.2K
BCWM
75
Bartlett & Co Wealth Management
Ohio
$60.8K

PJP Hedge Fund Activity: Q1 2026 in Review

119 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Invesco Pharmaceuticals ETF (PJP) for Q1 2026, worth a combined $151M — up 118% from $69.2M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new PJP positions and 11 closed out — a net gain of 17 holders — while 33 added to existing stakes and 21 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $24.4M. The largest seller was WBI Investments, exiting entirely with an estimated $739K sold.

  • 119 institutional investors held Invesco Pharmaceuticals ETF (PJP) as of Q1 2026, up from 105 in Q4 2025.
  • Funds reported $151M of Invesco Pharmaceuticals ETF stock for Q1 2026, up 118% quarter-over-quarter.
  • 28 funds opened new Invesco Pharmaceuticals ETF positions in Q1 2026 and 11 closed out, a net change of +17 holders.
  • The largest Invesco Pharmaceuticals ETF buyer in Q1 2026 was Morgan Stanley, an estimated $24.4M added.
  • The largest Invesco Pharmaceuticals ETF seller in Q1 2026 was WBI Investments, an estimated $739K sold.

Based on aggregated 13F filings for Q1 2026.